Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 8:42 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 21,226 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

NCT00362726
View directory record Official record
Conditions
HIV Infections
Interventions
Rosiglitazone maleate, Atazanavir Sulphate, Atazanavir Sulphate + Rosiglitazone maleate, Atazanavir Sulphate + Ritonavir, Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Nov 3, 2026, 8:42 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

NCT01998035
View directory record Official record
Conditions
Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions
RomiDEPsin 10 MG/M2, Oral 5-Azacitidine 100 MG, Romidepsin 14 MG/M2, Oral 5-Azacitidine 200 MG, Oral 5-Azacitidine 300 MG
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Nov 3, 2026, 8:42 AM EST
Recruiting Not applicable Interventional

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

NCT05643235
View directory record Official record
Conditions
Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Nov 3, 2026, 8:42 AM EST
Completed No phase listed Observational

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol

NCT07787117
View directory record Official record
Conditions
Asthma
Interventions
None (observational study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
8,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Not listed Phase 4 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy.

NCT00237068
View directory record Official record
Conditions
Asthma
Interventions
Lansoprazole; Solutab
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 1 Interventional

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

NCT00256191
View directory record Official record
Conditions
Neoplasms, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
TPI 287 Injection
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 15, 2007 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05633355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 17 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Phoenix, Arizona • Tempe, Arizona • Bryant, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 1 Interventional Results available

Co-Administration Of Methotrexate And CP-690,550

NCT01745055
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 (tofacitinib), Methotrexate (MTX)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Daytona Beach, Florida • Fort Lauderdale, Florida • Miramar, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Nov 3, 2026, 8:42 AM EST
Completed Not applicable Interventional Results available

Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol

NCT02047643
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Computer algorithm to initiate pump suspension
Device
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Nov 3, 2026, 8:42 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Endothelial Function, Arterial Stiffness and Components

NCT01439217
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
8 Years to 28 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Nov 3, 2026, 8:42 AM EST
Completed Not applicable Interventional

An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent

NCT00002091
View directory record Official record
Conditions
HIV Infections
Interventions
Pentoxifylline
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 8:42 AM EST
Terminated Phase 2 Interventional Results available

Preservation of Ovarian Function After Hematopoietic Cell Transplant

NCT01343368
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders
Interventions
Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
50 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants

NCT04212091
View directory record Official record
Conditions
HIV Infections
Interventions
PGT121.414.LS, VRC07-523LS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Nov 3, 2026, 8:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Promoting Altruism to Enhance Vaccine Acceptance

NCT04568590
View directory record Official record
Conditions
Vaccine Refusal
Interventions
educational intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Nov 3, 2026, 8:42 AM EST
Terminated Phase 3 Interventional

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

NCT05306574
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Telitacicept, Placebo
Biological
Lead sponsor
Vor Biopharma
Industry
Eligibility
12 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Anniston, Alabama • Mission Hills, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Completed Not applicable Interventional Results available

Building on Needle Exchange to Optimize Prevention & Treatment

NCT03567174
View directory record Official record
Conditions
Intravenous Drug Usage, HIV/AIDS
Interventions
Integrated care van (ICV)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 1 Interventional

CellCept in p-ANCA Vasculitis

NCT00405860
View directory record Official record
Conditions
MPO-ANCA Vasculitis, Microscopic Polyangiitis
Interventions
CellCept (mycophenolate mofetil)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Nov 3, 2026, 8:42 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

NCT04221477
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Fontana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Completed No phase listed Observational

Surgery Checklist and Process Improvement Surrounding Endoscopic Sinus Surgery

NCT01499719
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Checklist introduction / Pause
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Nov 3, 2026, 8:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

HIV Risk Reduction in Youth in the Bahamas

NCT00774592
View directory record Official record
Conditions
HIV Infections
Interventions
FOYC, Goal for it (GFI), Wonderous Wetlands, Caribbean Informed Parents and Children Together (CImPACT), Bahamian Focus on Older Youth (BFOOY), Health and Family Life Curriculum (HFLE)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
Not listed
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Nov 3, 2026, 8:42 AM EST
Completed Phase 3 Interventional Results available

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

NCT03652064
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
19
States / cities
Cerritos, California • Jacksonville, Florida • Fort Wayne, Indiana + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 8:42 AM EST
Not listed Phase 4 Interventional

Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV Infection

NCT04240509
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Emtricitabine / Tenofovir
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Nov 3, 2026, 8:42 AM EST
Completed No phase listed Observational

Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy

NCT00001899
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Nov 3, 2026, 8:42 AM EST
Completed No phase listed Observational

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

NCT04356339
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon-beta-1b (BETASERON, BAY 86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Nov 3, 2026, 8:42 AM EST